US · FENC
Fennec Pharmaceuticals Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Research Triangle Park, NC 27709
- Website
- fennecpharma.com
Price · as of 2024-12-31
$6.54
Market cap 233.9M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $164.38 | +2,413.46% |
| Intrinsic Value(DCF) | $9,369.02 | +143,157.19% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $9.40 | ||||
| 2018 | $6.37 | ||||
| 2019 | $7.50 | ||||
| 2020 | $7.70 | ||||
| 2021 | $5.47 | $35.14 | |||
| 2022 | $8.84 | $0.00 | $0.00 | ||
| 2023 | $9.66 | $193.31 | $0.00 | $0.00 | $0.00 |
| 2024 | $6.88 | $164.38 | $36,605.80 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Fennec Pharmaceuticals Inc.'s (FENC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $164.38
- Current price
- $6.54
- AI upside
- +2,413.46%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9,369.02
+143,157.19% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| FENC | Fennec Pharmaceuticals In… | $6.54 | 233.9M | +2,413% | +143,157% | — | — | -430.69 | -31.98 | 3.95 | 37.62 | — | -31.98 | 93.30% | 5.40% | -0.92% | 4.98% | -72.31% | -1.21% | -3.29 | 0.63 | 6.38 | 5.71 | -1.52 | -9733.00% | 12369.00% | -25738.00% | 14.37% | 3.90 | -759.68% | 0.00% | 0.00% | 13.40% | 70.28 | 6.69 | 3.80 | -2.39 |
| AARD | Aardvark Therapeutics, In… | $12.49 | 271.95M | — | — | — | — | -6.35 | -2.39 | — | -2.56 | -3.45 | -2.39 | 0.00% | — | — | 46.03% | 26.47% | -46.77% | -0.01 | — | 15.05 | 14.95 | 2.69 | 18393.00% | — | 21243.00% | -13.91% | -3.67 | 21.14% | 0.00% | 0.00% | 39.22% | -2.54 | -3.18 | — | -0.36 |
| AVTX | Avalo Therapeutics, Inc. | $17.50 | 197.65M | -16% | -59% | — | +1,518% | -1.80 | 0.47 | 143.03 | 1.04 | — | 0.51 | 182.99% | -15535.60% | -7965.76% | -50.06% | 26350.77% | -40.91% | 0.00 | — | 19.96 | 19.42 | 1.96 | -9713.00% | -7708.00% | 5908.00% | -77.77% | -7.05 | 18867.69% | 0.00% | 0.00% | 201.50% | 1.03 | 1.45 | -160.77 | -1.75 |
| BDTX | Black Diamond Therapeutic… | $2.47 | 140.73M | — | — | — | — | -1.48 | 1.24 | — | -0.35 | — | 1.24 | 0.00% | — | — | -69.67% | -898.81% | -49.55% | 0.27 | — | 4.92 | 4.79 | 0.18 | -3245.00% | — | -666.00% | -60.22% | -3.03 | -710.82% | 0.00% | 0.00% | 0.00% | -0.34 | -0.43 | — | -5.31 |
| CRBU | Caribou Biosciences, Inc. | $1.90 | 177.59M | +1,241% | -57% | — | +5,094% | -0.70 | 0.41 | 10.48 | 0.48 | -3.59 | 0.41 | 60.71% | -1667.16% | -1491.95% | -47.99% | -243.96% | -40.00% | 0.10 | — | 7.16 | 6.94 | -0.06 | 1957.00% | -7101.00% | 3794.00% | -138.12% | -4.51 | -211.89% | 0.00% | 0.00% | 0.00% | 0.47 | 0.54 | -7.83 | -1.96 |
| ENTA | Enanta Pharmaceuticals, I… | $14.30 | 332M | +189% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| EPRX | Eupraxia Pharmaceuticals … | $8.18 | 273.87M | — | — | — | — | -5.48 | 4.23 | — | -3.01 | — | 4.23 | 0.00% | — | — | -144.55% | 1233.17% | -93.26% | 0.00 | -44.74 | 11.10 | 10.74 | 0.92 | -3504.00% | — | 4455.00% | -21.32% | -9.67 | 955.80% | 0.00% | 0.00% | 17.10% | -2.78 | -3.59 | — | 19.45 |
| NAUT | Nautilus Biotechnology, I… | $2.42 | 305.66M | — | — | — | — | -4.96 | 1.87 | — | -4.18 | — | 1.87 | 0.00% | — | — | -32.27% | -69.30% | -27.20% | 0.19 | — | 13.33 | 13.00 | -0.34 | -1607.00% | — | -1517.00% | -17.74% | -6.38 | -53.89% | 0.00% | 0.00% | 0.05% | -3.28 | -4.22 | — | 2.18 |
| OBIO | Orchestra BioMed Holdings… | $4.38 | 247.32M | +415% | -61% | — | — | -2.55 | 4.73 | 59.04 | -1.65 | -20.99 | 4.73 | 92.27% | -2437.49% | -2313.27% | -120.84% | 365.45% | -71.21% | 0.50 | — | 4.27 | 4.13 | 0.09 | 1216.00% | -442.00% | 1005.00% | -32.65% | -3.12 | 288.99% | 0.00% | 0.00% | 0.00% | -1.64 | -2.07 | 39.98 | -5.45 |
| PRLD | Prelude Therapeutics Inco… | $2.76 | 210M | — | — | — | — | -0.44 | 0.42 | 7.97 | 0.43 | — | 0.42 | 100.00% | -1995.91% | -1816.76% | -69.01% | -756.99% | -56.12% | 0.14 | — | 5.30 | 5.21 | -0.04 | -1683.00% | — | -626.00% | -185.78% | -4.01 | -561.60% | 0.00% | 0.00% | 0.00% | 0.43 | 0.58 | -8.54 | -5.73 |
| RNAC | Cartesian Therapeutics, I… | $7.59 | 197.37M | +525% | +8% | — | — | -6.16 | -70.08 | 12.25 | -3.66 | — | -2.32 | 100.00% | -112.81% | -198.97% | 34.64% | 12.34% | -20.92% | -2.06 | — | 9.43 | 9.29 | 2.61 | -9339.00% | 4964.00% | -3621.00% | -6.87% | -1.03 | 9.21% | 0.00% | 0.00% | 27.83% | -6.33 | -8.48 | 7.14 | -1.29 |
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
- CEO
- Jeffrey S. Hackman
- Employees
- 32
- Beta
- 0.77
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9,369.02 ÷ $6.54) − 1 = +143,157.19% (DCF, example).